An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Stopped An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.

Conditions

• Advanced Non Small Cell Lung Cancer (NSCLC)

Interventions

• DRUG: AUY922
• DRUG: Docetaxel
• DRUG: Pemetrexed

Sponsor

Novartis Pharmaceuticals